The key factors driving the growth of this market include increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.
Breast Cancer Liquid Biopsy Market, by Circulating Biomarker
> Circulating Tumor Cells (CTCs) > Cell-free DNA (cfDNA) > Extracellular Vesicles (EVs) > Other Circulating Biomarkers*
*Other circulating biomarkers include circulating RNA (ctRNA and cfRNA) and cell-free protein biomarkers. Breast Cancer Liquid Biopsy Market, by End User
> Reference Laboratories > Hospitals and Physician Laboratories > Other End Users
Breast Cancer Liquid Biopsy Market, by Region
> North America > Europe > Asia Pacific > RoW
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report: Company Information
> Detailed analysis and profiling of additional market players (Up to 5) Country-wise market information for North America (US, Canada), and Europe (Germany, UK, France, Rest of Europe)
Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the cfDNA segment is expected to account for the largest share of the Breast Cancer Liquid Biopsy Market. The ability of cfDNA for easy and early assessment of patient prognosis and occurrence in other body fluids along with blood is driving the growth of the cfDNA segment in the Breast Cancer Liquid Biopsy Market.
Based on end user, the Breast Cancer Liquid Biopsy Market is segmented into reference laboratories, hospitals and physician laboratories, and other end users (research institutes, public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories owing to their well-equipped set up for genetic testing.
QIAGEN N.V. (Netherlands), Roche Diagnostics (US), and Illumina, Inc. (US) dominated the global breast cancer liquid biopsy market. Some of the other players competing in this market are Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).
Geographically, the global breast cancer liquid biopsy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of breast cancer in the US and Canada, technological advancements in breast cancer liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 email@example.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: